Chen Y H, Böck G, Vornhagen R, Steindl F, Katinger H, Dierich M P
Ludwig Boltzmann Institute for AIDS Research, Innsbruck, Austria.
Immunobiology. 1993 Aug;188(4-5):323-9. doi: 10.1016/s0171-2985(11)80216-0.
Based on our findings that HIV-1 gp41 independently of CD4 can bind to the human helper T lymphoid cell line H9, B cell line Raji and monocyte cell line U937, we characterized putative binding of HIV-1 gp41 to human peripheral blood lymphocytes (PBLs) and monocytes. Using flow cytometry (FACS), we demonstrated that the recombinant soluble HIV-1 gp41 (sgp41; Env amino acid 539-684) can bind to the normal human peripheral blood mononuclear cells (PBMCs), preferentially to B lymphocytes and monocytes independently of gp120-binding sites on CD4 molecules. This binding is dose-dependent. The HIV-1 sgp41 binds to blood B lymphocytes and monocytes more strongly than to T lymphocytes. By two-color flow cytometric analysis, we identified that sgp41 can bind 10% of CD4+ T lymphocytes, 11.9% of CD8+ T lymphocytes, 47% of CD19+ B lymphocytes and 44.2% of CD14+ monocytes.
基于我们的研究结果,即HIV-1 gp41可独立于CD4与人类辅助性T淋巴细胞系H9、B淋巴细胞系Raji和单核细胞系U937结合,我们对HIV-1 gp41与人类外周血淋巴细胞(PBL)和单核细胞的假定结合进行了表征。使用流式细胞术(FACS),我们证明重组可溶性HIV-1 gp41(sgp41;Env氨基酸539 - 684)可与正常人外周血单个核细胞(PBMC)结合,优先与B淋巴细胞和单核细胞结合,且不依赖于CD4分子上的gp120结合位点。这种结合是剂量依赖性的。HIV-1 sgp41与血液中的B淋巴细胞和单核细胞的结合比与T淋巴细胞的结合更强。通过双色流式细胞术分析,我们确定sgp41可与10%的CD4 + T淋巴细胞、11.9%的CD8 + T淋巴细胞、47%的CD19 + B淋巴细胞和44.2%的CD14 +单核细胞结合。